Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | SGN-TGT |
| Synonyms | |
| Therapy Description |
SGN-TGT is a nonfucosylated monoclonal antibody targeting the immune checkpoint inhibitor TIGIT that binds to its target on tumor-infiltrating lymphocytes, inhibiting the interaction of TIGIT with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of the anti-tumor immune response (NCI Drug Dictionary; Annals of Oncology. 2020 Sep 1;31:S729-30). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-TGT | SGN TGT|SEA-TGT|SGNTGT | TIGIT Antibody 17 | SGN-TGT is a nonfucosylated monoclonal antibody targeting the immune checkpoint inhibitor TIGIT that binds to its target on tumor-infiltrating lymphocytes, inhibiting the interaction of TIGIT with CD112 and CD155 and enhancing the interaction of CD112 and CD155 with CD226 expressed on immune cells, which may lead to activation of the anti-tumor immune response (NCI Drug Dictionary; Annals of Oncology. 2020 Sep 1;31:S729-30). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04254107 | Phase I | SGN-TGT Pembrolizumab + SGN-TGT | A Safety Study of SGN-TGT in Patients With Advanced Cancer | Recruiting | USA | ITA | FRA | ESP | CAN | 1 |
CKB BOOST